|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
trametinib + dabrafenib + AZD1775
Sensitive: D – Preclinical
Cancers (Basel) - 2 weeks
|
No biomarker
No biomarker
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
|
No biomarker
No biomarker
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
|
NTRK2 fusion
NTRK2 fusion
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
denosumab
Sensitive: A2 - Guideline
|
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
selpercatinib
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
pralsetinib
Sensitive: A2 - Guideline
|
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
trametinib + dabrafenib
Sensitive: C1 - Off-label
|
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
vemurafenib
Sensitive: C1 - Off-label
|
BRAF mutation
BRAF mutation
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
|
BRAF mutation
BRAF mutation
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
vemurafenib
Sensitive: C2 – Inclusion Criteria
|
BRAF mutation
BRAF mutation
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
PLX8394 + cobicistat
Sensitive: C3 – Early Trials
|
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
BGB-283
Sensitive: C3 – Early Trials
|
BRAF mutation
BRAF mutation
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
dabrafenib
Sensitive: C3 – Early Trials
|
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
cabozantinib tablet
Sensitive: C3 – Early Trials
|
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
siltuximab
Sensitive: C4 – Case Studies
|
PDGFRB overexpression
PDGFRB overexpression
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
larotrectinib
Sensitive: C4 – Case Studies
|
EGFR overexpression
EGFR overexpression
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
larotrectinib
Sensitive: C4 – Case Studies
|
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
dabrafenib + SNR1611
Sensitive: C4 – Case Studies
|
NCOA4-RET fusion
NCOA4-RET fusion
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
lenvatinib
Sensitive: C4 – Case Studies
|
TPM3-NTRK1 fusion
TPM3-NTRK1 fusion
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
AB106
Sensitive: C4 – Case Studies
|
GLI3 overexpression
GLI3 overexpression
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
larotrectinib
Sensitive: C4 – Case Studies
|
GLI2 overexpression
GLI2 overexpression
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
larotrectinib
Sensitive: C4 – Case Studies
|
GLI1 overexpression
GLI1 overexpression
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
larotrectinib
Sensitive: C4 – Case Studies
|
TPM3-NTRK1 fusion
TPM3-NTRK1 fusion
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
larotrectinib
Sensitive: C4 – Case Studies
|
NTRK1 overexpression
NTRK1 overexpression
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
larotrectinib
Sensitive: C4 – Case Studies
|
BRAF V600E + TERT mutation
BRAF V600E + TERT mutation
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
trametinib + dabrafenib
Resistant: C4 – Case Studies
|
BRAF V600E + TERT mutation
BRAF V600E + TERT mutation
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
sorafenib
Resistant: C4 – Case Studies
|
NRAS Q61K + BRAF V600E
NRAS Q61K + BRAF V600E
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
vemurafenib
Sensitive: C4 – Case Studies
|
PTEN R130del
PTEN R130del
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
MK-2206
Sensitive: D – Preclinical
|
BRAF mutation
BRAF mutation
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
PP2
Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
MK-2206
Sensitive: D – Preclinical
|
PIK3CA E545K
PIK3CA E545K
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
MK-2206
Sensitive: D – Preclinical
|
RET rearrangement
RET rearrangement
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
MK-2206
Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
dasatinib + CI-1040
Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
dasatinib
Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
cabozantinib capsule
Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
CI-1040 + SU6656
Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
CI-1040 + PP2
Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
CI-1040
Sensitive: D – Preclinical
|
RET-PTC1 rearrangement
RET-PTC1 rearrangement
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
AZD1480
Sensitive: D – Preclinical
|
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
AZD1480
Sensitive: D – Preclinical
|
|
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
|
AZD1480
Sensitive: D – Preclinical
|
